Details for Patent: 9,649,306
✉ Email this page to a colleague
Which drugs does patent 9,649,306 protect, and when does it expire?
Patent 9,649,306 protects ROZLYTREK and is included in one NDA.
This patent has thirty-one patent family members in seventeen countries.
Summary for Patent: 9,649,306
Title: | Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2- -(tetrahydro-pyran-4-ylamino)-benzamide |
Abstract: | The present invention relates to a process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2- -(tetrahydro-pyran-4-ylamino)-benzamide. Novel solid forms of this compound, their utility in treating diseases caused by deregulated protein kinase activity and pharmaceutical compositions containing them are also object of the present invention. |
Inventor(s): | Barbugian; Natale Alvaro (Milan, IT), Forino; Romualdo (Milan, IT), Fumagalli; Tiziano (Trezzano Rosa, IT), Orsini; Paolo (Legnano, IT) |
Assignee: | NERVIANO MEDICAL SCIENCES S.R.L. (Nerivano (MI), IT) |
Application Number: | 15/172,478 |
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 9,649,306
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genentech Inc | ROZLYTREK | entrectinib | CAPSULE;ORAL | 212725-001 | Aug 15, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION | ⤷ Try a Trial | ||||
Genentech Inc | ROZLYTREK | entrectinib | CAPSULE;ORAL | 212725-001 | Aug 15, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER | ⤷ Try a Trial | ||||
Genentech Inc | ROZLYTREK | entrectinib | CAPSULE;ORAL | 212725-002 | Aug 15, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION | ⤷ Try a Trial | ||||
Genentech Inc | ROZLYTREK | entrectinib | CAPSULE;ORAL | 212725-002 | Aug 15, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,649,306
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
12169139 | May 23, 2012 |
International Family Members for US Patent 9,649,306
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 091138 | ⤷ Try a Trial | |||
Australia | 2013265288 | ⤷ Try a Trial | |||
Australia | 2018201037 | ⤷ Try a Trial | |||
Brazil | 112014028841 | ⤷ Try a Trial | |||
Canada | 2873979 | ⤷ Try a Trial | |||
China | 104395308 | ⤷ Try a Trial | |||
China | 106167485 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |